Community-associated methicillin-resistant Staphylococcus aureus infection

Community-associated methicillin-resistant Staphylococcus aureus infection refers to infection caused by methicillin-resistant S. aureus in community settings, as distinguished from healthcare-associated MRSA infection in the supplied literature ^[2][3]. The sources frame CA-MRSA as a global epidemic and a distinct epidemiologic problem, while also noting that the concept is under active surveillance and interpretation rather than being presented here as a single standardized clinical syndrome ^[1][3]. Source-backed detail on formal diagnostic criteria or standardized surveillance case definitions is not yet available ^[1][2][3].

The provided sources indicate that CA-MRSA causes considerable morbidity and mortality and that infections are often recurrent ^[2]. They also note that clinicians have had to adapt empiric management for syndromes such as skin and soft tissue infection and pneumonia, implying that these are important clinical presentations within the source set ^[3]. Beyond this, the snippets do not provide a source-backed severity distribution, complication profile, or symptom chronology, so those details are not yet available here ^[2][3].

The sources describe CA-MRSA as increasingly common worldwide and as part of a global epidemic ^[2][3]. In Europe, by contrast, community-associated MRSA infection is described as relatively uncommon, even though MRSA bacteraemia affects all European countries with marked geographical variation and remains above 25% of S. aureus bacteraemia in more than one-third of countries in the cited 2008 surveillance data ^[1]. The literature also highlights transmission from colonized livestock, particularly pigs, to exposed workers such as farm workers, abattoir workers, and veterinarians, and notes that certain MRSA clones show geographic clustering within regional healthcare networks ^[1].

The sources emphasize that CA-MRSA is highly transmissible to close contacts and that outbreaks have shown skin-to-skin and skin-fomite contact as important and common routes of acquisition ^[2]. They also state that colonization may precede infection, while simultaneously cautioning that reliance on healthcare-associated transmission models may be inadequate for community-associated disease ^[2]. A livestock-associated pathway is also noted in Europe, with transmission from colonized pigs and other animals to occupationally exposed persons ^[1].

The clearest source-supported exposure group in the provided material is persons in close contact with cases, since infections are described as highly transmissible to close contacts ^[2]. Another explicitly noted risk context is occupational exposure to colonized livestock, especially pigs, among farm workers, abattoir workers, and veterinarians ^[1]. Beyond these groups, the supplied sources do not provide enough evidence to define additional high-risk populations with confidence ^[1][2][3].

The provided material points to prevention strategies centered on interrupting transmission, with particular attention to colonization, close-contact spread, and fomite-mediated spread ^[2]. It notes that intranasal topical antibiotics for nasal decolonization have been incorporated into some prevention efforts, but the same source cautions that prevention strategies based only on healthcare-associated MRSA models may be flawed for community-associated disease ^[2]. The literature also underscores antimicrobial stewardship as an important component of ongoing control efforts ^[3].

For surveillance purposes, CA-MRSA should be interpreted as a community-associated MRSA phenomenon that is globally relevant but heterogeneous in distribution and apparently less common in Europe than MRSA bacteraemia overall ^[1][2][3]. The sources suggest that reported burden may vary by region, clone, and exposure setting, including livestock-associated transmission in occupational groups and clustering within regional healthcare networks ^[1]. Source-backed detail on a unified surveillance threshold, laboratory definition, or case classification scheme is not yet available ^[1][2][3].

1. 1 Johnson AP et al. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011 May. PMID: 21521706. doi: 10.1093/jac/dkr076. PubMed: https://pubmed.ncbi.nlm.nih.gov/21521706/
2. 2 Miller LG et al. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008 Mar 1. PMID: 18220477. doi: 10.1086/526773. PubMed: https://pubmed.ncbi.nlm.nih.gov/18220477/
3. 3 Khan A et al. Current and future treatment options for community-associated MRSA infection. Expert Opin Pharmacother. 2018 Apr. PMID: 29480032. doi: 10.1080/14656566.2018.1442826. PubMed: https://pubmed.ncbi.nlm.nih.gov/29480032/
4. 4 Community-acquired methicillin-resistant Staphylococcus aureus infection. Journal of the American Academy of Dermatology. 2005. doi: 10.1016/j.jaad.2005.04.020. DOI: https://doi.org/10.1016/j.jaad.2005.04.020
5. 5 Community-Associated Methicillin-Resistant Staphylococcus aureus. Emergency Medicine Clinics of North America. 2008. doi: 10.1016/j.emc.2008.01.010. DOI: https://doi.org/10.1016/j.emc.2008.01.010
6. 6 Community-Associated Methicillin-Resistant Staphylococcus aureus. Pediatric Infectious Disease Journal. 2008. doi: 10.1097/inf.0b013e31818a3450. DOI: https://doi.org/10.1097/inf.0b013e31818a3450

ICD-10

B95.6

ICD-11

Total cases

14K

Peak month

2017-06

Coverage

1 reporting countries · 2007-01-01 → 2026-05-01